Gary Nachman
Recent Articles about ADMA Biologics Inc.
Asceniv Growth, Margin Expansion, and Pipeline Optionality Drive Price Target 04/23/2026
Canaccord Genuity initiates coverage of ADMA Biologics Inc. (ADMA:NASDAQ), citing Asceniv's differentiated hyperimmune IVIG profile, accelerating margins from yield enhancement, and an underappreciated pipeline.
© 2026 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
